Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in infections compared with cyclophosphamide (moderate certainty).
Azathioprine may leads to lower death compared with methotrexate (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Azathioprine showed no clear difference in relapse compared with methotrexate (low certainty).
Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).
Azathioprine may leads to lower severe adverse events compared with methotrexate (low certainty).
It is very uncertain whether azathioprine (AZA) changes death compared with mycophenolate mofetil (MMF) (very low certainty).
It is very uncertain whether azathioprine (AZA) changes ESKD compared with mycophenolate mofetil (MMF) (very low certainty).
Azathioprine (AZA) probably leads to higher renal relapse compared with mycophenolate mofetil (MMF) (moderate certainty).
Azathioprine (AZA) may leads to higher doubling of serum creatinine compared with mycophenolate mofetil (MMF) (low certainty).
Azathioprine (AZA) showed no clear difference in major infection compared with mycophenolate mofetil (MMF) (low certainty).
Azathioprine (AZA) may leads to higher leucopenia compared with mycophenolate mofetil (MMF) (low certainty).
Azathioprine (AZA) showed no clear difference in alopecia compared with mycophenolate mofetil (MMF) (low certainty).